{
  "abstract": "Su Jin Yim and colleagues argue that with the proposed definition of Alzheimer’s disease (AD) expanding in the most recent 2024 revision of clinical criteria by the Alzheimer’s Association Workgroup (AA), there will be a significantly increased risk of overdiagnosis and harm. This problem is compounded by the fact that the new disease-modifying drugs approved for mild cognitive impairment (MCI) and early AD do not show clinical improvement and cause serious adverse events.",
  "authors": [
    {
      "affiliations": [
        "University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada"
      ],
      "name": "Su Jin Yim"
    },
    {
      "affiliations": [
        "Johns Hopkins School of Medicine, Baltimore, Maryland, USA"
      ],
      "name": "Sevil Yasar"
    },
    {
      "affiliations": [
        "Johns Hopkins School of Medicine, Baltimore, Maryland, USA"
      ],
      "name": "Nancy Schoenborn"
    },
    {
      "affiliations": [
        "Emergency Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"
      ],
      "name": "Eddy Lang"
    }
  ],
  "title": "Expanded disease definitions in Alzheimer’s disease and the new era of disease-modifying drugs",
  "uid": "7784a967-89d3-5351-81b2-70a907d03959"
}